Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM
Neurological Research · 01.02.2023 · 45 (2) · 112-117
DOI: 10.1080/01616412.2022.2124792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Research, online erschienen am 02.10.2022. Verfasst von Zanga Gisela und 54 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Neurologia. Hospital Cesar Milstein, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: The author(s) reported that there is no funding associated with the work featured in this article..
Abstract (Originalsprache)
INTRODUCTION: The discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS) is commonly seen in real-world settings due to several factors. AREA COVER: The aim of this study is to describe the frequency of disease activity after discontinuation of DMTs in MS patients included in the Argentinean MS and NMOSD registry. DISCUSION: Patients with relapsing remitting MS (RRMS) and active secondary progressive MS (SPMS) were included based on the following criteria: they discontinued treatment for more than 6 months, they had been treated with a DMT for ≥2 years, and they had at least 6 months of follow-up in the registry after discontinuation. Demographic and clinical data were collected. Disease activity during follow-up was defined as the presence of a clinical relapse or a new magnetic resonance (MRI) lesion (either new lesions on T2-weighted sequence and/or contrast enhancement). Bivariate analysis was applied to identify clinical and demographic factors related to disease activity. CONCLUSION: We included 377 patients (75.5% RRMS, 22.5% SPMS) who had discontinued DMTs. The mean (SD) follow-up after discontinuation was 15.7 (7.9) months. After discontinuation, the presence of relapse was detected in 18.8% and 3.5% in RRMS and SPMS, respectively; and new MRI activity in 22% and 3.5%, respectively. We found that higher risk of relapse and MRI activity was associated with younger age (p < 0.001), shorter disease duration (p < 0.001), and RRMS phenotype (p = 0.006). Males showed higher MRI activity (p 0.011). This study provides real-world data that can guide physicians when considering discontinuation of DMTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Neurologia. Hospital Cesar Milstein, Buenos Aires, Argentina.
- Servicio de Neurología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
- Centro de esclerosis múltiple de Buenos Aires, CABA, Buenos Aires, Argentina.
- Centro de Investigaciones Diabaid, CABA.
- Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología, Hospital de Clínicas José de San Martín, CABA.
- Departamento de Enfermedades desmielinizantes - Sanatorio Allende, Córdoba.
ORCID-Profile: Zanga Gisela
Förderung
- The author(s) reported that there is no funding associated with the work featured in this article.
Zitieren
APA
Gisela, Z., Carla, P., Josefina, B., Tomas, I., Lucia, B., Pappolla, A., Miguez, J., Patrucco, L., Cristiano, E., Norma, D., Verónica, T., Carlos, V., Leila, C., Alonso, R., Garcea, O., Silva, B., Celica, Y., Marrodan, M., Gaitán, M. I., …, & RELEVAREM Study Group. (2023). Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM. Neurological Research, 45(2), 112-117. https://doi.org/10.1080/01616412.2022.2124792
Vancouver
Gisela Z, Carla P, Josefina B, Tomas I, Lucia B, Pappolla A, et al. Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM. Neurological Research. 2023;45(2):112-117. doi:10.1080/01616412.2022.2124792
BibTeX
@article{Gisela2023,
author = {Gisela, Zanga and Carla, Portinari and Josefina, Barber and Tomas, Ibañez and Lucia, Brolese and Pappolla, Agustín and Miguez, Jimena and Patrucco, Liliana and Cristiano, Edgardo and Norma, Deri and Verónica, Tkachuk and Carlos, Vrech and Leila, Cohen and Alonso, Ricardo and Garcea, Orlando and Silva, Berenice and Celica, Ysrraelit and Marrodan, Mariano and Gaitán, María I and Correale, Jorge and Marcos, Burgos and Luciana, Lázaro and Anibal, Chertcoff and Emanuel, Silva and Eduardo, Knorre and Judith, Steinberg and Dario, Tavolini and Javier, Hryb and Pedro, Nofal and Felisa, Leguizamon and Pablo, Lopez A and Susana, Liwacki and Patricio, Blaya and Raul, Piedrabuena and Adriana, Carra and Alejandra, Martinez and María Eugenia, Balbuena and Contentti Edgar, Carnero and Amelia, Alves Pinheiro and Carolina, Mainella and Mariano, Coppola and Luciano, Recchia and Matias, Kohler and Eduardo, Kohler and María Celeste, Curbelo and Maria Laura, Menichini and Santiago, Tizio and Mariela, Cabrera and Fatima, Pagani Cassará and Andres, Barboza and Geraldine, Luetic and Alonso Serena, Marina and Juan Ignacio, Rojas and Marcos, Sorbara and RELEVAREM Study Group., RELEVAREM Study Group.},
title = {Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM},
journal = {Neurological Research},
year = {2023},
volume = {45},
number = {2},
pages = {112--117},
doi = {10.1080/01616412.2022.2124792}
}
EUVIMED